General Counsel
Axsome Therapeutics, Inc. (AXSM)Equibles does not estimate personal net worth.
Get an email with a short summary when Axsome Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AXSM alertsHunter Murdock is recorded as General Counsel at Axsome Therapeutics, Inc. (AXSM). The newest filing on record that lists Hunter Murdock as General Counsel at Axsome Therapeutics, Inc. (AXSM) is dated April 24, 2026. The proxy statement of Axsome Therapeutics, Inc. reports total compensation of $3,224,304 for Hunter Murdock in fiscal 2025, including a base salary of $530,000. Disclosed compensation is on record for 5 fiscal years. Hunter Murdock has spoken on 4 earnings calls across 1 company, most recently for Axsome Therapeutics, Inc. on May 5, 2025. Axsome Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Axsome Therapeutics, Inc. includes Herriot Tabuteau (CEO), Nick Pizzie (CFO), Mark Jacobson (COO) and 3 others.
“I'll answer the first part, and then I'll turn it over to Herriot for the second part. For the first part, Teva has a 180-day regulatory exclusivity. So regardless of what happens, Teva will be the first generic to launch.”
“I will address the first part, and then Nick, do you want to handle the second part?”
“As a matter of practice, we really can't comment on ongoing legal proceedings, but, you know, I can tell you we're very proud of our extensive portfolio on Auvelity, and we don't have any further comment on it.”
“As we've previously announced earlier this month, we did receive the paragraph 4 notice from Teva related to Auvelity. The receipt of the letter is normal, being part of the Hatch-Waxman process.”
Start not stated–present
Last confirmed April 24, 2026
Proxy statement
Start not stated–2022-04-22
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
General Counsel
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | General Counsel | $530,000 | $3,224,304 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | General Counsel | $505,000 | $3,245,542 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | General Counsel | $485,000 | $3,057,530 |
| 2022 | Axsome Therapeutics, Inc. (AXSM) | General Counsel | $450,000 | $2,484,699 |
| 2021 | Axsome Therapeutics, Inc. (AXSM) | General Counsel | $350,000 | $374,431 |
